Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InvestorPlace's Louis Navellier believes all Ocugen needs is a catalyst. On Oct. 4, OCGN stock got two.

Ocugen Stock Needs a Catalyst for Growth That Probably Isn't Coming

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 18.5% in Tuesday's regular trading session, extending gains to a second straight day. What Happened: Ocugen's shares extended their rally on Tuesday after it was reported that an expert panel of India's drug regulator has recommended Bharat Biotech's COVID-19 vaccine, Covaxin, for children between the age of two and 18.

Is This Going To Be The Next Big Factor For Ocugen (OCGN) Stock?

Moderna

Novavax

Vaxart

Ocugen Inc. (NASDAQ:OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine Covaxin, for children between the ages of 2 and 18. Ocugen is partnered with Bharat Biotech.

Why Ocugen Stock Is Rallying While Moderna, Novavax, Vaxart Can't Catch Up

The shares of Ocugen Inc (NASDAQ:OCGN) are flying up the charts today, last seen 17% higher to trade at $9.

Drug Stock Pops on Partnered Covid-19 Vaccine Update

ESS Tech

Inmode Ltd

Lithium Americas Corp

Nutriband

Progenity

Quanterix

R.R. Donnelley & Sons

Tata Motors

Penny stocks are on the move Tuesday and we're taking a look at what's hot among traders of the volatile investments today. The post Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers appeared first on InvestorPlace.

Hot Penny Stocks for Tuesday: Today's 10 Biggest Movers

OCGN stock is making its investors quite happy this morning and prompting many more to pile in. The company is receiving crucial approval.

OCGN Stock: One Big Reason Ocugen Is Powering Higher Today

A positive regulatory development in India is sending the biotech's shares higher today.

Why Ocugen Stock Is on Fire Today

OCGN stock could be at a full value today given its revenue prospects but could still rise if its Covaxin vaccine gains approval outside India. The post Ocugen Will Have Value If Its Covid Vaccine Can Get Approved appeared first on InvestorPlace.

Ocugen Will Have Value If Its Covid Vaccine Can Get Approved

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 15% pre-market today. This is why it happened.

OCGN Stock: Why It Increased Today

Admittedly, one last boost may still be on the table, if meme traders use subsequent WHO news as reason to send OCGN stock back to double-digit prices. But with its high chances of ultimately collapsing in price, it's a stock most investors should avoid.

Don't Buy Too Much Into the WHO Hype Surrounding Ocugen Stock

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday's regular trading session and also gained 11.4% in the after-hours session. What Happened: Ocugen's shares rallied on Monday despite no company-specific news.

Why Did Ocugen Stock Skyrocket On Monday?

Southwest Airlines

SoFi Technologies

Tesla

AT&T

SoFi, Southwest Airlines, Tesla, AT&T and Ocugen were our top stock trades for Tuesday. Now, let's look at how the charts are setting up.

5 Top Stock Trades for Tuesday: SOFI, LUV, TSLA, T, OCGN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues to investigate Ocugen, Inc. (NasdaqCM: OCGN). On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Use Authorization process that it had previously stated

OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN

The World Health Organization said a decision on the Emergency Use Listing (EUL) of India's COVID-19 vaccine, Covaxin, will be finalized next week. Ocugen Inc (NASDAQ: OCGN) is the U.S. partner for the vaccine.

WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources

The FDA seems highly unlikely to approve the Covaxin vaccine, making OCGN stock an excellent name to short going forward. The post Ocugen Bulls Are Overlooking Its FDA Approval Hurdles appeared first on InvestorPlace.

Ocugen Bulls Are Overlooking Its FDA Approval Hurdles

The shares of Ocugen Inc (NASDAQ:OCGN) are surging, up 6.7% to trade at $7.20 at last check.

Deal-Making Biotech Stock Charges Higher

OCGN stock is surging on some big news. The World Health Organization could give the company the go-ahead on its Covid-19 vaccine very soon.

OCGN Stock: 2 Huge Reasons Ocugen Stock Is Shooting Higher Today

The WHO's nod of approval wont be fruitful to OCGN stock in blowing past the regulatory hurdles in the North American Covid 19 vaccine market The post WHO Approval Won't Move Ocugen Stock Very Much Over the Long Term appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

WHO Approval Won't Move Ocugen Stock Very Much Over the Long Term

An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today. Covaxin is India's indigenously-developed COVID-19 vaccine, in collaboration with Ocugen Inc (NASDAQ: OCGN).

WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today

AMC Entertainment

Coinbase

GameStop

Robinhood

Popularity doesn't always translate to profitability on Wall Street.

5 Ultra-Popular Stocks to Avoid Like the Plague in October

OCGN stock holders should be patient as the World Health Organization's potential approval of an important vaccine could happen soon. The post Ocugen Stock Just Needs a Catalyst to Break Free appeared first on InvestorPlace.

Ocugen Stock Just Needs a Catalyst to Break Free

Hope is one thing, but for investors in OCGN stock expecting regulators or other bulls to come to the rescue is looking less likely The post It's Time To Drop Ocugen Stock While You Still Can appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

It's Time To Drop Ocugen Stock While You Still Can

Atea Pharmaceuticals

Atea Pharmaceuticals and Ocugen may be gearing up for a stellar October.

2 Best Biotech Stocks to Buy In October

CRISPR Therapeutics

Nikola

These companies could deliver jaw-dropping revenue growth through mid-decade.

4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years

Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock.

News for Ocugen, Inc. Stock (OCGN)